OncoImmunology, June 2020
Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy, Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM
Vila-Leahey A, MacKay A , Portales-Cervantes L, Weir GM , Merkx-Jacques A, Stanford MM
Human Vaccines and Immunotherapeutics, June 2020
Evaluation of the protective potential of antibody and T cell responses elicited by a novel preventative vaccine towards respiratory syncytial virus small hydrophobic protein
Torrey HL, Kaliaperumal V, Bramhecha Y, Weir GM, Falsey AR, Walsh EE, Langley JM, Schepens B, Saelens X, Stanford MM.
J Infect Dis, July 2018
A Respiratory Syncytial Virus Vaccine Based on the Small Hydrophobic Protein Ectodomain Presented With a Novel Lipid-Based Formulation Is Highly Immunogenic and Safe in Adults: A First-in-Humans Study
Langley JM, MacDonald LD, Weir GM, MacKinnon-Cameron D, Ye L, McNeil S, Schepens B, Saelens X, Stanford MM, Halperin SA. J Infect Dis.